Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Baceca plus Tazarotene versus Tazarotene plus placebo in basal cell carcinoma
2005-001474-27Phase 2Completed
- Sponsor
- TopoTarget
- Start
- Jun 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in basal cell carcinoma (BCC) comparing Baceca + tazarotene with Tazarotene + placebo (2 arms). Primary endpoint: Primary composite efficacy endpoint. Started Jun 2005; status: completed.
02
Drugs
belinostattazarotene
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2005-001474-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001474-27.